Newsletter

Stay up to date on all things heart attack. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Women’s Heart Attack Research Program

June 11, 2019

Overview

 

This clinical trial examines a higher than normal number of platelets, platelet genetic composition, and the effects of platelets in women who have had or are at higher risk for heart attack.

 

Study Information

 

This is an observational, cohort, study, with a 6 month follow up. There is an estimated 200 participants. The study began in August 2016 and is expected to be completed by April 2020.

 

Inclusion Criteria

 

  • Females, ages 21 to 99 years old
  • Acute blood deficiency symptoms compatible with diagnosis of myocardial infarction (MI), such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms
  • Objective evidence of MI (either or both of the following):
    • Elevation of troponin to above the laboratory upper limit of normal (ULN)
    • ST segment elevation of ≥1mm on 2 contiguous ECG leads
  • Willing to provide informed consent and comply with all aspects of the protocol
  • Administration of aspirin at least 1 hour before cardiac catheterization
  • Administration of thienopyridine (e.g., clopidogrel, ticagrelor) at least 1 hour before cardiac catheterization
  • Women with ≥50% of any major epicardial vessel on invasive angiography may participate

 

Exclusion Criteria

 

  • Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month)
  • Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, or cardic trauma
  • Pregnant
  • Thrombolytic therapy for a full-blown heart attack, otherwise known as ST elevation myocardial infarction (STEMI
  • Use of any of the following medications:
  • Platelet antagonists (except aspirin and thienopyridines) within 7 days
  • NSAIDs (e.g., ibuprofen, naproxen) within 3 days.
  • Thrombocytopenia (platelet count <100,000)
  • Thrombocytosis (platelet count >500,000)
  • Anemia (hemoglobin <9 mg/dl)
  • Hemorrhagic diathesis

 

Location

 

You may participate in this clinical trial at NYU Langone Medical Center in New York, New York, United States, 10016. Contact Jeffrey Berger, MD if you have any questions or concerns.

 

Sponsors/Collaborators

 

This study is being sponsored by NYU Langone Medical Center with Harmony R Reynolds, MD at the Principal Investigator.

Clinical Trials

View All

Testing a Community Intervention to Increase Aspirin Use

Recently, there is a growing consensus that aspirin, when appropriately used, reduces cardiovascular death in men,…

MRI of Myocardial Infarction

Heart failure (HF) affects approximately 5.1 million people in the US and is the cause of 250,000 deaths each year.…

Impact of Daylight on Patients With Acute Myocardial Infarction

Damage from a heart attack usually occurs during the early morning hours. Therefore, the circadian system is…

CLEAR SYNERGY Neutrophil Substudy

CLEAR SYNERGY is an international, randomized placebo controlled trial of the poisonous alkaline colchicine and…

Evaluating Vitamin D Normalization on Cardiovascular-Related Events

This study evaluates whether achieving 25-hydroxyvitamin D, or  25[OH] Vit D (what vitamin D is converted into…

The Impact of Early Follow-up on Readmission Rates in AMI Patients

This study aims to conduct the first randomized, prospective trial to better clear up the association between early…

Testosterone Replacement and Exercise Capacity in Hypogonadal Men

This study examines the effect of testosterone replacement on the ability to exercise for men with functional…

Make a comment and share this article on your profile.

Write a comment for your publication

Successfully Shared!

View on my Profile

Send this to a friend